Episode 56. Management of Newly Diagnosed CML with Dr. Hagop Kantarjian

In this episode, we discuss the management of CML with Dr. Hagop Kantarjian from MD Anderson Cancer Center. Here are the key articles we discussed: 

 

1. ASC4FIRST RCT: Asciminib in newly diagnosed CML. 

https://pubmed.ncbi.nlm.nih.gov/38820078/

 

2. 5-year follow-up of ENESTnd RCT (nilotinib): 

https://pubmed.ncbi.nlm.nih.gov/26837842/

 

3. 10-year follow-up of ENESTnd RCT (nilotinib): 

https://pubmed.ncbi.nlm.nih.gov/33414482/

 

4. 10-year follow-up of CML-IV RCT (imatinib): 

https://pubmed.ncbi.nlm.nih.gov/25676422/

 

5. MD Anderson data on low-dose dasatinib (50 mg): 

https://pubmed.ncbi.nlm.nih.gov/36054032/

https://pubmed.ncbi.nlm.nih.gov/31553487/

 

6. CML: 2025 update on diagnosis, therapy, and monitoring: 

https://pubmed.ncbi.nlm.nih.gov/39093014/

 

What is Blood Cancer Talks?

This is a podcast on latest advances in the understanding and management of blood cancers. Here, we will bring a wide range of experts within hematologic malignancies to discuss various topics in depth.
Host: Raj Chakraborty, MD from Columbia University, New York, Ashwin Kishtagari, MD, from Vanderbilt University, Nashville, and Edward Cliff, MD, from Harvard University, Boston
Tweet your suggestions and feedback to @rajshekharucms @AshKishtagari @Eddie_Cliff @BloodCancerTalk